Loading…
Quick answer: Butylated Hydroxyanisole carries the heavier risk profile. Retinyl palmitate is restricted in the EU and allowed in the US; Butylated Hydroxyanisole is — in the EU and — in the US.
| Property | Retinyl palmitate | Butylated Hydroxyanisole |
|---|---|---|
| EU status | Restricted | — |
| US status | Allowed | — |
| Risk level | medium | — |
| Banned in | — | Japan (banned for use in foods containing fats and oils) |
| Restricted in | European Union | European Union (restricted; banned in baby food), United Kingdom, Australia/New Zealand (ADI-based limits) |
| Category | endocrine disruptor | additive |
| Where it hides | anti-aging cream, sunscreen, lotion | — |
Retinyl palmitate is a vitamin A ester used in anti-aging skincare and sunscreen.
Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum. It is a mixture of two isomeric compounds (2-BHA and 3-BHA). BHA prevents fats and oils from oxidizing (going rancid), extending shelf life. Its chemical formula is C11H16O2.
Retinyl palmitate: The EU caps vitamin A levels over concerns it may accelerate skin damage in sunlight; the US does not restrict it.
Butylated Hydroxyanisole: BHA is classified by the International Agency for Research on Cancer (IARC) as Group 2B (possible human carcinogen) based on studies showing it causes papillomas and squamous cell carcinomas of the forestomach in rats, hamsters, and mice at high doses. A 1983 NTP bioassay confirmed these findings. The National Toxicology Program lists BHA as 'reasonably anticipated to be a human carcinogen' in its Report on Carcinogens. The forestomach is an anatomical structure found in rodents but not humans, creating some uncertainty about direct extrapolation. EFSA's 2012 re-evaluation (EFSA Journal 2012;10(10):2588) concluded that BHA may have endocrine-disrupting potential based on animal data showing interactions with estrogen receptors and androgenic hormone pathways. EFSA found the ADI of 1 mg/kg body weight but noted concerns about endocrine effects. Japan banned BHA for use in foods containing fats and oils, consistent with its generally precautionary approach to synthetic food preservatives. In cosmetics, the EU Scientific Committee on Consumer Safety (SCCS) has assessed BHA and found potential endocrine-disrupting effects at dermal exposure levels. EWG rates BHA as high-concern in Skin Deep cosmetics database. The antioxidant paradox applies: while BHA prevents lipid oxidation in foods, it may paradoxically act as a pro-oxidant in certain biological contexts at certain doses.
Scan a barcode and we'll flag both Retinyl palmitate and Butylated Hydroxyanisole (plus 200+ other ingredients banned overseas).
Scan free →